Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 4Completed 4Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × itacitinib × Clear all
NCT05823571 2025-09-18

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
32 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡